【瑞穗:核心新药NMRA-861销售有望达12亿美元 上调Neumora(NMRA.US)目标价至5美元】智通财经APP

智通财经
Jul 21, 2025
【瑞穗:核心新药NMRA-861销售有望达12亿美元 上调Neumora(NMRA.US)目标价至5美元】智通财经APP获悉,瑞穗分析师Graig Suvannavejh发表研报,将Neumora Therapeutics(NMRA.US)目标价从4美元上调至5美元,并维持“跑赢大盘”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10